UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis

Primary endpoint at week 16 was met for all three active doses of oral orismilast in moderate to severe patients with psoriasis. Statistical significance...

Related Keywords

Taiwan ,Japan ,United States ,Hong Kong ,United Kingdom ,China ,Manchester ,Germany ,Salford ,Denmark ,Italy ,Poland ,Spain ,France ,Macau ,Hellerup ,Hovedstaden ,Innovent Biologics ,Richard Warren ,Kim Kj ,Sarah Toft ,Morten Boesen ,Decision Resources Group Psoriasis ,University Of Manchester ,Psoriasis Activity ,Severity Index ,Consultant Dermatologist ,Salford Royal ,Signatory Investigator ,Chief Executive Officer ,New Drug ,Fast Track ,Mainland China ,Seven Major Markets ,Decision Resources Group Psoriasis Report ,Clinical Presentation ,Chief Financial Officer ,Union Therapeutics ,